Our mission is to save this generation of children and young adults with Duchenne muscular dystrophy.
CureDuchenne is recognized as the global leader in research, patient care and innovation for improving and extending the lives of those with Duchenne.
We operate with integrity through compassion, and empowering the community nationally with positive solutions.Our actions fuel hope for families, enable progress for drug development, and extend ambulation for patients in collaboration with pharmaceutical companies, medical and healthcare professionals, our scientific advisory board, and our board of directors.
With a mission to cure Duchenne muscular dystrophy, CureDuchenne breaks the traditional charitable mold and balances passion with business acumen. Our innovative venture philanthropy model funds groundbreaking research, early diagnosis and treatment access. With pioneering education and support programs, our organization drives real change for those with Duchenne muscular dystrophy and their loved ones. 81% of every dollar goes to research and mission critical programs. 12 projects funded by CureDuchenne have progressed to clinical trials. We’ve raised over $35M for research, education and care. CureDuchenne contributed early funding for the first FDA-approved Duchenne drug. Our venture philanthropy model has leveraged $2.3B in follow-on funding for future programs from investors and biotech companies.